| [1] |
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版). 临床肝胆病杂志,2015,31:1941-1960.
|
| [2] |
Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014, 61:777-784.
|
| [3] |
Chen S, Zhang W. HBeAg-positive chronic hepatitis B patients with prior long-time exposure to nucleos(t)ide analogues: “switch-to” or “addon” PegIFN alfa, that is the question. J Hepatol, 2015, 62:239.
|
| [4] |
刘洁,漆俊,胥富波,等. 干扰素、核苷(酸)类似物单独及二者序贯治疗HBeAg阳性慢性乙型肝炎的比较. 中国肝脏病杂志(电子版),2015,7:59-63.
|
| [5] |
Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol, 2013, 58:676-683.
|
| [6] |
European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol, 2012, 57:167-185.
|
| [7] |
Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology, 2012, 143:963-973.
|
| [8] |
Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol. 2013, 58:205-209.
|
| [9] |
Enomoto M, Nishiguchi S, Tamori A, et al. Long-term outcome of sequential therapy with lamivudine followed by interferon-β in nucleoside-naive, hepatitis B e-antigen-positive patients with chronic hepatitis B virus genotype C infection. J Interferon Cytokine Res, 2015, 35:613-620.
|
| [10] |
Li GJ, Yu YQ, Chen SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother, 2015, 59:4121-4128.
|
| [11] |
Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding peginterferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: a multicenter randomized trial (ARES study). Hepatology, 2015, 61:1512-1522.
|
| [12] |
Boglione L, Cusato J, Allegra S, et al. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res, 2014, 102:35-43.
|
| [13] |
Boglione L, Cusato J, De Nicolo A, et al. Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. J Viral Hepat, 2015, 22:318-327.
|
| [14] |
Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology, 2010, 139:483-490.
|
| [15] |
Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013, 59:709-716.
|
| [16] |
Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology, 2013, 58: 923-931.
|
